Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetes mellitus is a metabolic disease with a growing prevalence worldwide, affecting 171 million people in 2000 and an expected 366 million people in 2030 (1) and therefore diabetic nephropathy is rapidly increasing in the Western hemisphere and represents in up to 50 % the cause of end stage renal disease. Hence, early intervention is desirable to prevent any damage to the kidneys. In the early stage of diabetic nephropathy, endothelium dysfunction is a key pathogenetic process as indicated by increased leakage of albumin through the glomerular barrier (2).

Hence, improvement of endothelium function is an attractive therapeutic goal of antidiabetic medication. Endothelial dysfunction, in particular basal nitric oxide activity, has been also identified as pivotal determinant of glomerular filtration rate (3).

A new and promising class of antidiabetic drugs are the gliptins. Gliptins act by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the rapid inactivation of glucagon-like peptide-1 (GLP-1) - an incretin hormone of the gut (6 - 8), thereby enhancing and prolonging the effects of GLP-1. GLP-1 - member of the incretin hormones - is released into the blood after meal ingestion and stimulates the insulin secretion in a glucose dependent manner. This accounts for the marked prandial insulin response, which prevents prandial hyperglycemia.

Apart from surrogate parameters like reduction of fasting and postprandial blood glucose levels or improvement of HbA1c, the effect of gliptins on micro- and macrovascular function and cardiovascular outcome has not been the primary focus of current studies. However, infusion of GLP-1, the incretin hormone affected by gliptins has been reported to ameliorate endothelial dysfunction in patients suffering from coronary artery disease (9) and it was recently shown that infusion of GLP-1 into healthy human subjects increases both normal and ACh-induced vasodilatation (10). In studies on rats with diabetes, GLP-1 infusion nearly re-established their normal vascular tone (11) and there are further data from experimental animals that indicate a beneficial effect of GLP-1 on endothelial function (12).

It is of major interest whether therapy with gliptins improves endothelial function of the micro- and macrovasculature. In face of the burden that diabetic nephropathy causes, the effect of linagliptin on the renal vasculature and endothelium integrity of the renal circulation (as measured by the availability of nitric oxide), is a key stone in order to claim that linagliptin is an effective antidiabetic agents. There is a need to demonstrate that linagliptin is effective beyond its blood glucose lowering actions and improves vascular endothelium function in the kidney.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Linagliptin

Criteria

Inclusion Criteria:

• Female and male patients aged between 18 and 70 years

• Type 2 diabetes without diabetic nephropathy (definition see exclusion criteria)

Exclusion Criteria:

• Any other form of diabetes mellitus than type 2 diabetes mellitus

• Use of insulin, glitazone or gliptins within the past 3 months

• Any other oral antidiabetic drug that can not be discontinued for the study period.

• Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion

• Urinary albumin excretion (UACR) > 100 mg/g (early morning spot urine)

• eGFR <45 ml/min/1.73m² (MDRD Formula)

• Uncontrolled arterial hypertension (RR ≥180/ ≥110mmHg)

• HbA1c ≥ 10%

• Fasting plasma glucose ≥ 240 mg/dl

• Body mass index ≥ 40 kg/m²

• Triglyceride levels ≥ 1000 mg/dl

• HDL-cholesterol levels <25 mg/dl

• Overt congestive heart failure (CHF) or history of CHF

• Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmacokinetics of study drugs

• Significant laboratory abnormalities such as SGOT or SGPT levels more than 3 x above the upper limit of normal range, serum creatinine > 2mg/dl

• Drug or alcohol abuses

• Pregnant or breast-feeding patients

• Any patient currently receiving chronic (>30 consecutive days) treatment with an oral corticosteroid

• Patients being treated for severe auto immune disease e.g. lupus

• Participation in another clinical study within 30 days prior to visit 1

• Individuals at risk for poor protocol or medication compliance

• Subject who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V